Ian Karp | Senior Vice President, Investor Relations and Corporate Communications |
John Leonard | Chief Executive Officer |
David Lebwohl | Chief Medical Officer |
Laura Sepp-Lorenzino | Chief Scientific Officer |
Glenn Goddard | Chief Financial Officer |
Joseph Thome | TD Cowen |
Maury Raycroft | Jefferies |
Yanan Zhu | Wells Fargo Securities |
Dae Gon Ha | Stifel |
Liisa Bayko | Evercore ISI |
William Pickering | Bernstein |
Joon Lee | Truist |
Brian Cheng | JPMorgan |
Rick Bienkowski | Cantor Fitzgerald |
Steve Seedhouse | Raymond James |
Silvan Tuerkcan | JMP Securities |
Richard Law | Credit Suisse |
Good morning and welcome to the Intellia Therapeutics' First Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the Company's request and will be available on the Company's website following the end of the call.
As a reminder, all participants are currently in a listen-only mode.